David Jayabalan

2.0k total citations
71 papers, 992 citations indexed

About

David Jayabalan is a scholar working on Hematology, Molecular Biology and Oncology. According to data from OpenAlex, David Jayabalan has authored 71 papers receiving a total of 992 indexed citations (citations by other indexed papers that have themselves been cited), including 58 papers in Hematology, 47 papers in Molecular Biology and 32 papers in Oncology. Recurrent topics in David Jayabalan's work include Multiple Myeloma Research and Treatments (58 papers), Protein Degradation and Inhibitors (28 papers) and Cancer Treatment and Pharmacology (16 papers). David Jayabalan is often cited by papers focused on Multiple Myeloma Research and Treatments (58 papers), Protein Degradation and Inhibitors (28 papers) and Cancer Treatment and Pharmacology (16 papers). David Jayabalan collaborates with scholars based in United States, Germany and China. David Jayabalan's co-authors include Rubén Niesvizky, Roger Pearse, Morton Coleman, Selina Chen‐Kiang, Tomer M. Mark, Scott Ely, Faiza Zafar, Paul J. Christos, John P. Leonard and Karen Pekle and has published in prestigious journals such as Journal of Biological Chemistry, Journal of Clinical Investigation and Journal of Clinical Oncology.

In The Last Decade

David Jayabalan

69 papers receiving 976 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
David Jayabalan United States	16	562	540	396	169	149	71	992
Xiujin Ye China	16	326 0.6×	526 1.0×	253 0.6×	70 0.4×	236 1.6×	94	984
Guido Bisping Germany	17	436 0.8×	458 0.8×	302 0.8×	106 0.6×	106 0.7×	28	845
Alexandros Spyridonidis Greece	20	281 0.5×	594 1.1×	272 0.7×	63 0.4×	234 1.6×	75	1.1k
Tina Bagratuni Greece	16	550 1.0×	224 0.4×	195 0.5×	163 1.0×	169 1.1×	45	1.1k
Yoshihiro Kameoka Japan	17	563 1.0×	294 0.5×	330 0.8×	61 0.4×	220 1.5×	64	1.3k
James K. Mangan United States	18	345 0.6×	514 1.0×	347 0.9×	108 0.6×	194 1.3×	64	1.1k
Ravindran Ankathil Malaysia	22	649 1.2×	225 0.4×	318 0.8×	107 0.6×	92 0.6×	99	1.3k
Yukiko Komeno Japan	20	549 1.0×	445 0.8×	112 0.3×	102 0.6×	189 1.3×	44	984
F. Dreyfus France	15	462 0.8×	645 1.2×	441 1.1×	56 0.3×	256 1.7×	56	1.2k
Fabrizio Carnevale‐Schianca Italy	15	366 0.7×	505 0.9×	666 1.7×	54 0.3×	539 3.6×	37	1.2k

Countries citing papers authored by David Jayabalan

Since Specialization

Citations

This map shows the geographic impact of David Jayabalan's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by David Jayabalan with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites David Jayabalan more than expected).

Fields of papers citing papers by David Jayabalan

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by David Jayabalan. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by David Jayabalan. The network helps show where David Jayabalan may publish in the future.

Co-authorship network of co-authors of David Jayabalan

This figure shows the co-authorship network connecting the top 25 collaborators of David Jayabalan. A scholar is included among the top collaborators of David Jayabalan based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with David Jayabalan. David Jayabalan is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Jayabalan, David, Zachary J. Walker, Diana Abbott, et al.. (2023). CD38 antibody re-treatment in daratumumab-refractory multiple myeloma after time on other therapies. Blood Advances. 7(21). 6430–6440. 16 indexed citations

Jayabalan, David, Jorge Monge, Cara A. Rosenbaum, et al.. (2022). Advances in the molecular characterization of multiple myeloma and mechanism of therapeutic resistance. Frontiers in Oncology. 12. 1020011–1020011. 7 indexed citations

Atrash, Shebli, Philippe Thompson‐Leduc, Ming‐Hui Tai, et al.. (2022). Patient characteristics, treatment patterns, and outcomes among black and white patients with multiple myeloma initiating daratumumab: A real-world chart review study. Clinical Lymphoma Myeloma & Leukemia. 22(8). e708–e715. 1 indexed citations

Zhou, Liang, David Jayabalan, Rubén Niesvizky, et al.. (2020). Caspase-8 Inhibition Prevents the Cleavage and Degradation of E3 Ligase Substrate Receptor Cereblon and Potentiates Its Biological Function. Frontiers in Cell and Developmental Biology. 8. 605989–605989. 6 indexed citations

Ely, Scott, Peter A. Forsberg, Adriana Rossi, et al.. (2017). Cellular Proliferation by Multiplex Immunohistochemistry Identifies High-Risk Multiple Myeloma in Newly Diagnosed, Treatment-Naive Patients. Clinical Lymphoma Myeloma & Leukemia. 17(12). 825–833. 6 indexed citations

Nayar, Utthara, Jonathan Reichel, Gunkut Akar, et al.. (2017). Identification of a nucleoside analog active against adenosine kinase–expressing plasma cell malignancies. Journal of Clinical Investigation. 127(6). 2066–2080. 9 indexed citations

Forsberg, Peter A., Adriana Rossi, Roger Pearse, et al.. (2016). Carfilzomib Induction with Lenalidomide and Clarithromycin Consolidation and Lenalidomide Maintenance (CarBiRD) for Multiple Myeloma (MM). Blood. 128(22). 4518–4518. 4 indexed citations

Mark, Tomer M., Angelique Boyer, Adriana Rossi, et al.. (2015). Clapd (Clarithromycin, Pomalidomide, Dexamethasone) Therapy in Relapsed or Refractory Multiple Myeloma Overcomes Negative Prognostic Impact of Adverse Cytogenetics and Prior Resistance to Lenalidomide and Bortezomib. Blood. 126(23). 4232–4232. 6 indexed citations

Niesvizky, Rubén, Tomer M. Mark, Maureen Ward, et al.. (2013). Overcoming the Response Plateau in Multiple Myeloma: A Novel Bortezomib-Based Strategy for Secondary Induction and High-Yield CD34+ Stem Cell Mobilization. Clinical Cancer Research. 19(6). 1534–1546. 20 indexed citations

10.

Geyer, Julia T., Rubén Niesvizky, David Jayabalan, et al.. (2013). IgG4 plasma cell myeloma: new insights into the pathogenesis of IgG4-related disease. Modern Pathology. 27(3). 375–381. 21 indexed citations

11.

Jungbluth, Achim A., Maurizio DiLiberto, Xiangao Huang, et al.. (2011). MAGE-A Inhibits Apoptosis in Proliferating Myeloma Cells through Repression of Bax and Maintenance of Survivin. Clinical Cancer Research. 17(13). 4309–4319. 79 indexed citations

12.

Zafar, Faiza, et al.. (2010). An evaluation of the role of bone marrow biopsy in patients with multiple myeloma who achieve an unconfirmed stringent complete remission.. Journal of Clinical Oncology. 28(15_suppl). 8144–8144. 1 indexed citations

13.

Baughn, Linda B., Maurizio Di Liberto, Rubén Niesvizky, et al.. (2009). CDK2 Phosphorylation of Smad2 Disrupts TGF-β Transcriptional Regulation in Resistant Primary Bone Marrow Myeloma Cells. The Journal of Immunology. 182(4). 1810–1817. 29 indexed citations

14.

Niesvizky, Rubén, Scott Ely, David Jayabalan, et al.. (2009). A Phase I Trial of PD 0332991, a Novel, Orally-Bioavailable CDK4/6-Specific Inhibitor Administered in Combination with Bortezomib and Dexamethasone to Patients with Relapsed and Refractory Multiple Myeloma.. Blood. 114(22). 1877–1877. 5 indexed citations

15.

Goel, Sanjay, Marvin L. Cohen, Lionel Perrin, et al.. (2008). The Effect of Ketoconazole on the Pharmacokinetics and Pharmacodynamics of Ixabepilone: A First in Class Epothilone B Analogue in Late-Phase Clinical Development. Clinical Cancer Research. 14(9). 2701–2709. 21 indexed citations

16.

Mark, Tomer M., David Jayabalan, Morton Coleman, et al.. (2008). Atypical serum immunofixation patterns frequently emerge in immunomodulatory therapy and are associated with a high degree of response in multiple myeloma. British Journal of Haematology. 143(5). 654–660. 33 indexed citations

17.

Mark, Tomer M., Jessica Stern, Jessica Furst, et al.. (2008). Stem Cell Mobilization with Cyclophosphamide Overcomes the Suppressive Effect of Lenalidomide Therapy on Stem Cell Collection in Multiple Myeloma. Biology of Blood and Marrow Transplantation. 14(7). 795–798. 79 indexed citations

18.

Niesvizky, Rubén, Tara Naib, Paul J. Christos, et al.. (2007). Lenalidomide‐induced myelosuppression is associated with renal dysfunction: adverse events evaluation of treatment‐naïve patients undergoing front‐line lenalidomide and dexamethasone therapy. British Journal of Haematology. 138(5). 640–643. 68 indexed citations

19.

Niesvizky, Rubén, Déborah Martı́nez-Baños, Jessica Jalbrzikowski, et al.. (2007). Prophylactic low-dose aspirin is effective antithrombotic therapy for combination treatments of thalidomide or lenalidomide in myeloma. Leukemia & lymphoma. 48(12). 2330–2337. 39 indexed citations

20.

Combs, Terry P., Shankar Mukherjee, Cecília J. G. de Almeida, et al.. (2005). The Adipocyte as an Important Target Cell for Trypanosoma cruzi Infection. Journal of Biological Chemistry. 280(25). 24085–24094. 162 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact